Center for Biomedical Imaging, Department of Radiology, New York University School of Medicine, New York, NY, USA; Tech4Health Institute, New York University Langone Health, New York, NY, USA.
Center for Biomedical Imaging, Department of Radiology, New York University School of Medicine, New York, NY, USA; Musculoskeletal Section, Diagnostic Imaging Departament, Hospital Universitario de la Fundación Santa Fe de Bogota, Bogota, Colombia.
Osteoarthritis Cartilage. 2022 Feb;30(2):329-340. doi: 10.1016/j.joca.2021.11.006. Epub 2021 Nov 11.
One driving factor in the progression to posttraumatic osteoarthritis (PTOA) is the perpetuation of the inflammatory response to injury into chronic inflammation. Molecular imaging offers many opportunities to complement the sensitivity of current imaging modalities with molecular specificity. The goal of this study was to develop and characterize agents to image hyaluronan (HA)-mediated inflammatory signaling.
We developed optical (Cy5.5-P15-1) and magnetic resonance contrast agents (Gd-DOTA-P15-1) based in a hyaluronan-binding peptide (P15-1) that has shown anti-inflammatory effects on human chondrocytes, and validated them in vitro and in vivo in two animal models of PTOA.
In vitro studies with a near infrared (NIR) Cy5.5-P15-1 imaging agent showed a fast and stable localization of Cy5.5-P15-1 on chondrocytes, but not in synovial cells. In vivo NIR showed significantly higher retention of imaging agent in PTOA knees between 12 and 72 h (n = 8, Cohen's d > 2 after 24 h). NIR fluorescence accumulation correlated with histologic severity in cartilage and meniscus (ρ between 0.37 and 0.57, P < 0.001). By using in vivo magnetic resonance imaging with a Gd-DOTA-P15-1 contrast agent in 12 rats, we detected a significant decrease of T1 on injured knees in all cartilage plates at 48 h (-15%, 95%-confidence interval (CI) = [-18%,-11%]) while no change was observed in the controls (-2%, 95%-CI = [-5%,+1%]).
This study provides the first in vivo evidence that hyaluronan-related inflammatory response in cartilage after injury is a common finding. Beyond P15-1, we have demonstrated that molecular imaging can provide a versatile technology to investigate and phenotype PTOA pathogenesis, as well as study therapeutic interventions.
创伤后骨关节炎(PTOA)进展的一个驱动因素是损伤后炎症反应持续存在为慢性炎症。分子成像提供了许多机会,可以用分子特异性补充当前成像方式的敏感性。本研究的目的是开发和表征用于成像透明质酸(HA)介导的炎症信号的试剂。
我们开发了基于透明质酸结合肽(P15-1)的光学(Cy5.5-P15-1)和磁共振对比剂(Gd-DOTA-P15-1),该肽已显示出对人软骨细胞的抗炎作用,并在两种 PTOA 动物模型中进行了体外和体内验证。
近红外(NIR)Cy5.5-P15-1 成像剂的体外研究表明,Cy5.5-P15-1 快速且稳定地定位于软骨细胞,但不在滑膜细胞上。体内 NIR 显示,在 PTOA 膝关节中,成像剂在 12 至 72 小时之间的保留率显著更高(n=8,24 小时后 Cohen's d>2)。NIR 荧光积累与软骨和半月板的组织学严重程度相关(ρ值在 0.37 到 0.57 之间,P<0.001)。通过在 12 只大鼠中使用 Gd-DOTA-P15-1 对比剂进行体内磁共振成像,我们在所有软骨板的受伤膝关节中均检测到 48 小时时 T1 的显著降低(-15%,95%-置信区间(CI)=-18%,-11%),而在对照组中未观察到变化(-2%,95%-CI=-5%,+1%)。
本研究首次提供了体内证据,表明损伤后软骨中的透明质酸相关炎症反应是一种常见发现。除 P15-1 外,我们还证明了分子成像可以提供一种多功能技术来研究和表型化 PTOA 发病机制,以及研究治疗干预措施。